Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Personalis $125 million stock offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $125 million…
IDEAYA Biosciences $50 million at-the-market offering
Davis Polk advised the sales agent on the SEC-registered at-the-market offering by IDEAYA Biosciences, Inc. of its…
Atreca $100 million at-the-market offering
Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Atreca, Inc. of its common stock for up…
Freeline Therapeutics Holdings $158.8 million IPO
Davis Polk advised Freeline Therapeutics Holdings plc on its $158.8 million initial public offering of 8,823,529 American…
Horizon Therapeutics $963.5 million share offering
Davis Polk advised the representatives of the underwriters in connection with an approximately $963.5 million public…
Acutus Medical $170 million IPO
Davis Polk advised Acutus Medical, Inc. on its SEC-registered initial public offering of 10,147,058 shares of common stock…
Oak Street Health $377.3 million IPO
Davis Polk advised the joint book running managers in connection with the $377.3 million initial public offering of 17,968…
Tigermed HK$10.7 billion IPO and Hong Kong listing
Davis Polk advised Hangzhou Tigermed Consulting Co., Ltd. in connection with its initial public offering and listing on the…
Turning Point Therapeutics $250 million at-the-market offering
Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Turning Point Therapeutics, Inc. of its…
BioXcel Therapeutics $200 million stock offering
Davis Polk advised the underwriters in connection with the SEC-registered offering by BioXcel Therapeutics, Inc. of 4,000…